Experts hope that renaming a condition that can often affect women’s fertility and diabetes risk – and which, in numerous cases, goes undiagnosed – may help more patients receive the care and treatment they need.
Polycystic ovarian syndrome, or PCOS, can present as cysts in the ovaries. However, the condition can include many more symptoms, including irregular menstrual cycles, difficulty getting pregnant, female-patterned baldness, type 2 diabetes and cardiovascular disease, according to the World Health Organisation (WHO).
Globally, around 10% to 13% of reproductive age women world are impacted by PCOS, but an estimated 70% don’t know they have it, and one reason could be that the name is not very descriptive of the actual condition, said Dr Helena Teede, an Endocrinologist and Professor of Women’s Health at Monash University in Australia, according to CNN.
Teede, who is leading the process to change the name, is lead author of a paper published recently in The Lancet on the name change.
Over her more than 25-year career, Teede said she’s had to dispel misunderstandings that lead people to think the condition is just about cysts on the ovaries, which has resulted in missed diagnoses and inaccurate treatment.
The Lancet paper officially changes the name of the condition to one that researchers hope can provide more clarity: polyendocrine metabolic ovarian syndrome, or PMOS.
It isn’t just about cysts
A primary goal of the new name is to give importance to the wide range of impacts the condition has on those who have it.
“By calling this condition polycystic ovary, we’re missing the big picture,” said Dr Alla Vash-Margita, Associate Professor of Obstetrics, Gynaecology and Reproductive Sciences at Yale University, and division chief for Paediatric Adolescent Gynaecology at the Yale School of Medicine.
“There was a lot of stigma and myth related to this name. People thought they have large cysts, which they do not have,” she said.
The syndrome was first seen as a reproductive disorder, said Dr Andrea Dunaif, Professor of Medicine in the division of endocrinology at the Icahn School of Medicine at Mount Sinai in New York.
It was found to be associated with a slight increase in male hormone levels that can cause irregular periods and fertility issues. Then, in the 1980s, she said that researchers found it was also associated with insulin resistance, or the body not responding to normal circulating levels of insulin.
“The body has to produce more insulin, and if the body can’t kind of keep up with the needs, then diabetes can develop,” Dunaif said.
Since then, research has suggested it is a major metabolic disorder, with increased risks for conditions like liver and heart disease, she added.
More recently, other symptoms have also been associated with PMOS, including sleep apnoea, depression, anxiety and body dysmorphia, Vash-Margita said.
A name to take seriously
The “polyendocrine” part of the new name better describes it as an endocrine or hormone condition, Teede said. People with PMOS have a disturbance in the endocrine (or chemical messenger system) of the body, which can lead to widespread impacts, she added.
The road to changing the name took 14 years and worldwide collaboration of 56 patient and professional organisations, according to the Lancet paper.
“This shift will reframe the conversation and demand it is taken as seriously as the long-term, complex health condition it is,” said Rachel Morman, chair of Verity PCOS UK.
The hope is that a new name will help give the condition the attention it deserves, Dunaif said. Physicians in the gynaecology field have done a pretty good job of taking the condition seriously, but because PMOS impacts so many parts of the body, all kinds of medical specialties should be more aware and collaborate to effectively treat patients.
Many in the field are excited about the new name change, but Dunaif worries that it still doesn’t quite capture the latest understandings of the condition.
For example, family histories suggest that women without ovaries may also be affected by the metabolic aspects of this condition, she said. And the name might be more accurate if it broke it up into subtypes such as for patients who primarily experience reproductive symptoms or those who have metabolic symptoms, she said.
Vash-Margita, however, thinks PMOS is a name that reflects the realities of the mental and physical impacts much better and “captures the condition in a much better way, reflecting multiple changes that occur”, she said.
A term that better captures that reality may carve the way for better diagnoses, new treatments and increased insurance coverage for the condition, added Dr Christina Boots, associate Professor of Obstetrics and Gynaecology at Northwestern’s Feinberg School of Medicine.
“Women’s health is notoriously underfunded,” she said. “Recognising that it really spans not just reproductive issues, but mental health and metabolic health as well, might help enhance the number of dollars and the number of studies that are to understand it and treat it.”
Diagnosis
One vital sign is a history of irregular menstrual cycles, Dunaif said. Having eight or fewer menstrual cycles a year, or cycles that last than 40 days, is a sign a woman should be evaluated for a hormonal problem.
Doctors should check the patient’s hormones for insulin resistance or elevated androgen, a hormone which can cause things like acne, balding or increased body hair.
Much of the current medical approach to PMOS is managing symptoms rather than treating the underlying cause, including lifestyle changes toward a balanced diet and increased exercise.
Vash-Margita pointed out that weight loss has been associated with improvement in PMOS symptoms.
Medications can be prescribed for the metabolic symptoms, and GLP-1s have been found to be helpful, although there are no major trials in women with PMOS, Dunaif said.
Birth control pills are commonly used to regulate menstrual cycles and reduce the hormones that can cause body hair, acne and hair loss, while fertility treatments may help induce ovulation in women trying to conceive children with this condition.
Still, the answer to treating PMOS isn’t just patients knowing what to look for and what to do. One key in good PMOS treatment is finding healthcare providers who can really take the time to look at the whole picture and make good referrals to make a plan together, Boots said.
“Somebody’s dietician tells them one thing, their psychiatrist tells them another thing, and their dermatologist tells them something else, so they’ve got so many players who are in their niche and often don’t see the full picture,” she said.
“Seeing these patients as people, and doing our best to give them care with empathy and individualising their care… is so important.”
Study details
Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process
Helena Teede, Mahnaz Bahri Khomami, Rachel Morman et al.
Published in The Lancet on 12 May 2026
Summary
Polyendocrine metabolic ovarian syndrome (PMOS), previously named polycystic ovary syndrome (PCOS), affects one in eight women. However, the term PCOS is inaccurate, implying pathological ovarian cysts, obscuring diverse endocrine and metabolic features, and contributing to delayed diagnosis, fragmented care, and stigma, while curtailing research and policy framing. Building on an international mandate for change, we outline an unprecedented, rigorous, multistep global consensus process for the name change. Funding and governance were established with engagement of 56 leading academic, clinical, and patient organisations. Using iterative global surveys (with responses from 14 360 people with PCOS and multidisciplinary health professionals from all world regions), modified Delphi methods, nominal group technique workshops, and marketing and implementation analyses, we identified principles prioritising scientific accuracy, clarity, stigma avoidance, cultural appropriateness, and implementation feasibility. An accurate new name was prioritised over retaining the PCOS acronym or a generic name. Implementation approaches prioritised evolution rather than transformation. Preferred terms were polyendocrine, metabolic, and ovarian, reflecting the condition's multisystem pathophysiology, and polyendocrine metabolic ovarian syndrome was the consensus new name. Accuracy was improved by omitting cysts and by capturing endocrine, metabolic, and ovarian dysfunction. A co-designed global implementation strategy, including a transition period, education, and alignment with health systems and disease classification, is under way.
CNN article – PCOS, a condition impacting millions of women worldwide, gets a new name (Open access)
See more from MedicalBrief archives:
Gut bacteria tied to fertility issues in women with PCOS – Chinese study
PCOS tied to cognitive decline, suggests US study
Major gaps in education and support for women with PCOS